A large proportion of patients with triple-negative breast cancer (TNBC) are treated with neoadjuvant chemotherapy. Approximately one-third of patients will achieve a pathologic complete response with neoadjuvant chemotherapy and have favorable outcomes. In contrast, two-thirds of patients will have residual disease and are at high risk of relapse.
1 Methods that can detect the presence of minimal residual disease (MRD) in the circulation after surgery may be used to determine in which patients disease will recur.